Skip to main content
ROIV
NASDAQ Life Sciences

Roivant Posts Unexpected Q4 Profit of $355.7M Driven by $770M Moderna Settlement

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$28.1
Mkt Cap
$20.19B
52W Low
$10.58
52W High
$30.33
52W Position info
166% above low
Off High info
7.4% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ROIV has more than doubled off its 52-week low of $10.58.

Summary

Roivant Sciences reported an unexpected Q4 net profit of $355.7 million, significantly beating analyst expectations for income from operations. This positive swing was primarily driven by a substantial $770 million gain from a litigation settlement with Moderna. While the company's previous 10-Q mentioned positive legal updates, the specific financial impact and the resulting unexpected profit were not disclosed, making this new and material information. This one-time gain provides a significant boost to the company's financials and demonstrates a successful resolution to a legal dispute. Looking ahead, Roivant anticipates launching brepocitinib in dermatomyositis by late September 2026 and expects topline Phase 3 data for brepocitinib in non-infectious uveitis and Phase 2 data for mosliciguat in PH-ILD in the second half of 2026, which are key catalysts for future growth.

At the time of this announcement, ROIV was trading at $28.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.2B. The 52-week trading range was $10.58 to $30.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

ROIV - Latest Insights

ROIV
Nov 09, 2026, 7:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.37
Real-time Price: $38.35 info
Change: -$3.02 (-7%) info
Market Cap: $28.048B info
ROIV
Nov 09, 2026, 7:17 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.00
Real-time Price: $38.35 info
Change: -$2.65 (-6%) info
Market Cap: $28.048B info
ROIV
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $40.39
Real-time Price: $38.35 info
Change: -$2.04 (-5%) info
Market Cap: $28.048B info
ROIV
Oct 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.20
Real-time Price: $38.35 info
Change: +$2.15 (+6%) info
Market Cap: $28.048B info
ROIV
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.60
Real-time Price: $38.35 info
Change: +$1.75 (+5%) info
Market Cap: $28.048B info